These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17691957)

  • 1. Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications.
    Cai L
    Curr Med Chem; 2007; 14(20):2193-203. PubMed ID: 17691957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of metallothionein reduces diabetic cardiomyopathy.
    Liang Q; Carlson EC; Donthi RV; Kralik PM; Shen X; Epstein PN
    Diabetes; 2002 Jan; 51(1):174-81. PubMed ID: 11756338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation.
    Wang J; Song Y; Elsherif L; Song Z; Zhou G; Prabhu SD; Saari JT; Cai L
    Circulation; 2006 Jan; 113(4):544-54. PubMed ID: 16432057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and metallothionein.
    Li X; Cai L; Feng W
    Mini Rev Med Chem; 2007 Jul; 7(7):761-8. PubMed ID: 17627587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.
    Cai L; Wang Y; Zhou G; Chen T; Song Y; Li X; Kang YJ
    J Am Coll Cardiol; 2006 Oct; 48(8):1688-97. PubMed ID: 17045908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy.
    Cai L
    Free Radic Biol Med; 2006 Sep; 41(6):851-61. PubMed ID: 16934665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic cardiomyopathy - Zinc preventive and therapeutic potentials by its anti-oxidative stress and sensitizing insulin signaling pathways.
    Cai L; Tan Y; Watson S; Wintergerst K
    Toxicol Appl Pharmacol; 2023 Oct; 477():116694. PubMed ID: 37739320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
    Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L
    J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent hypoxia-induced cardiomyopathy and its prevention by Nrf2 and metallothionein.
    Zhou S; Yin X; Jin J; Tan Y; Conklin DJ; Xin Y; Zhang Z; Sun W; Cui T; Cai J; Zheng Y; Cai L
    Free Radic Biol Med; 2017 Nov; 112():224-239. PubMed ID: 28778483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection.
    Xu J; Wang G; Wang Y; Liu Q; Xu W; Tan Y; Cai L
    J Cell Mol Med; 2009 Aug; 13(8A):1499-512. PubMed ID: 19583814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc and the diabetic heart.
    Song Y; Wang J; Li XK; Cai L
    Biometals; 2005 Aug; 18(4):325-32. PubMed ID: 16158224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of metallothionein gene expression by oxidative stress and metal ions.
    Andrews GK
    Biochem Pharmacol; 2000 Jan; 59(1):95-104. PubMed ID: 10605938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling.
    Wang Y; Feng W; Xue W; Tan Y; Hein DW; Li XK; Cai L
    Diabetes; 2009 Jun; 58(6):1391-402. PubMed ID: 19324938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adaptive immune role of metallothioneins in the pathogenesis of diabetic cardiomyopathy: good or bad.
    Ge T; Yu Y; Cui J; Cai L
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H264-H275. PubMed ID: 31100011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy.
    Li B; Tan Y; Sun W; Fu Y; Miao L; Cai L
    Toxicol Mech Methods; 2013 Jan; 23(1):27-33. PubMed ID: 23039870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc treatment prevents type 1 diabetes-induced hepatic oxidative damage, endoplasmic reticulum stress, and cell death, and even prevents possible steatohepatitis in the OVE26 mouse model: Important role of metallothionein.
    Liang T; Zhang Q; Sun W; Xin Y; Zhang Z; Tan Y; Zhou S; Zhang C; Cai L; Lu X; Cheng M
    Toxicol Lett; 2015 Mar; 233(2):114-24. PubMed ID: 25617602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes, metallothionein, and zinc interactions: a review.
    Islam MS; Loots du T
    Biofactors; 2007; 29(4):203-12. PubMed ID: 18057551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metallothionein prevents cardiac pathological changes in diabetes by modulating nitration and inactivation of cardiac ATP synthase.
    Cong W; Zhao T; Zhu Z; Huang B; Ma W; Wang Y; Tan Y; Chakrabarti S; Li X; Jin L; Cai L
    J Nutr Biochem; 2014 Apr; 25(4):463-74. PubMed ID: 24629910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy.
    Giacconi R; Cai L; Costarelli L; Cardelli M; Malavolta M; Piacenza F; Provinciali M
    Biofactors; 2017 Nov; 43(6):770-784. PubMed ID: 28845600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect and mechanisms of zinc supplementation in protecting against diabetic cardiomyopathy in a rat model of type 2 diabetes.
    Lu Y; Liu Y; Li H; Wang X; Wu W; Gao L
    Bosn J Basic Med Sci; 2015 Feb; 15(1):14-20. PubMed ID: 25725139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.